Heart failure in beta thalassemia: A 5-year follow-up study

被引:103
作者
Kremastinos, DT
Tsetsos, GA
Tsiapras, DP
Karavolias, GK
Ladis, VA
Kattamis, CA
机构
[1] Univ Athens, Onassis Cardiac Surg Ctr, Dept Cardiol 2, Athens Pediat Dept 1, Athens 17674, Greece
[2] Agia Sophia Hosp, Athens, Greece
关键词
D O I
10.1016/S0002-9343(01)00879-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To evaluate the survival of patients with beta thalassemia and heart failure who were treated with iron chelation therapy. SUBJECTS AND METHODS: Fifty-two consecutive patients with beta thalassemia and heart failure were followed in a prospective 5-year study. All patients underwent a full clinical examination with chest radiograph, electrocardiogram, and echocardiographic investigation performed at 6-month intervals or when a new symptom developed. RESULTS: Of the 52 patients (mean [+/-SD] age, 24 +/- 5 years), 25 (48%) survived 5 years after the onset of heart failure. Forty-three patients had left-sided heart failure, and 9 had right-sided heart failure. Those with left-sided heart failure were younger at presentation with heart failure (22 +/- 4 years vs. 31 +/- 6 years; P <0.001), had lower ejection fractions (36% +/- 9% vs. 64% +/- 10%; P <0.001), and had a lower mean serum ferritin level (3355 +/- 1241 ng/mL vs. 6,397 +/- 1,613 ng/mL; P <0.001). CONCLUSION: The 5-year survival rate in patients with beta thalassemia with heart failure was greater than previously reported. There are clinical characteristics that may make patients more likely to develop left- or right-sided heart failure. (C) 2001 by Excerpta Medica.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 25 条
[1]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[2]  
DWYER J, 1987, CLIN EXP IMMUNOL, V68, P621
[3]   Apolipoprotein E ε4 allele as a genetic risk factor for left ventricular failure in homozygous β-thalassemia [J].
Economou-Petersen, E ;
Aessopos, A ;
Kladi, A ;
Flevari, P ;
Karabatsos, F ;
Fragodimitri, C ;
Nicolaidis, P ;
Vrettou, H ;
Vassilopoulos, D ;
Karagiorga-Lagana, M ;
Kremastinos, DT ;
Petersen, MB .
BLOOD, 1998, 92 (09) :3455-3459
[4]  
Ehlers K H, 1980, Ann N Y Acad Sci, V344, P397
[5]   LATE CARDIAC COMPLICATIONS OF CHRONIC SEVERE REFRACTORY ANEMIA WITH HEMOCHROMATOSIS [J].
ENGLE, MA ;
ERLANDSON, M ;
SMITH, CH .
CIRCULATION, 1964, 30 (05) :698-&
[6]   CARDIOPULMONARY ASSESSMENT IN BETA-THALASSEMIA MAJOR [J].
GRISARU, D ;
RACHMILEWITZ, EA ;
MOSSERI, M ;
GOTSMAN, M ;
LAFAIR, JS ;
OKON, E ;
GOLDFARB, A ;
HASIN, Y .
CHEST, 1990, 98 (05) :1138-1142
[7]   COLOR DOPPLER ASSESSMENT OF MITRAL REGURGITATION WITH ORTHOGONAL PLANES [J].
HELMCKE, F ;
NANDA, NC ;
HSIUNG, MC ;
SOTO, B ;
ADEY, CK ;
GOYAL, RG ;
GATEWOOD, RP .
CIRCULATION, 1987, 75 (01) :175-183
[8]   ROLE OF OXYGEN-DERIVED FREE-RADICALS IN THE PATHOGENESIS OF COXSACKIEVIRUS-B3 MYOCARDITIS IN MICE [J].
HIRAOKA, Y ;
KISHIMOTO, C ;
TAKADA, H ;
KUROKAWA, M ;
OCHIAI, H ;
SHIRAKI, K ;
SASAYAMA, S .
CARDIOVASCULAR RESEARCH, 1993, 27 (06) :957-961
[9]   FERRITIN IN SERUM OF NORMAL SUBJECTS AND PATIENTS WITH IRON-DEFICIENCY AND IRON OVERLOAD [J].
JACOBS, A ;
WARDROP, CA ;
WORWOOD, M ;
BEAMISH, MR ;
MILLER, F .
BRITISH MEDICAL JOURNAL, 1972, 4 (5834) :206-&
[10]   Diagnosis and management of iron-induced heart disease in Cooley's anemia [J].
Jessup, M ;
Manno, CS .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :242-250